PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	~~to be assigned~~ Daniel Kolker
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Ancolio et al., alpha-Synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal	
		degradation in HEK293 and neuronal cells.	
		Neurosci. Lett., 285: 79-82, 2000	
		Anglade et al., Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease.	
		Histol. Histopathol., 12: 25-31, 1997	
		Baba et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.	
		Am. J. Pathol., 152: 879-884, 1998	
		Brunk et al., Exposure of cells to nonlethal concentrations of hydrogen peroxide induces degeneration-repair mechanisms involving lysosomal	
		destabilization.	
✓		Free Radic. Biol. Med., 19: 813-822, 1995	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Burke, Apoptosis in degenerative diseases of the basal ganglia.	
		The Neuroscientist, 4: 301-311, 1998	
		Bursch et al., programmed cell death (PCD). Apoptosis, autophagic PCD, or others?	
		Ann. NY Acad. Sci., 926: 1-12, 2000	
		Cavanagh et al., Routes of excretion of neuronal lysosomal dense bodies after ventricular infusion of leupeptin in the rat: a study using ubiquitin and	
		PGP 9.5 immunocytochemistry.	
		J. Neurocytol., 22: 779-791, 1993	
		Ciechanover, The ubiquitin-proteasome pathway: on protein death and cell life.	
		EMBO J., 17: 7151-7160, 1998	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Clayton and George, The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration, and disease.	
		Trends Neurosci., 21: 249-254, 1998	
		Clayton and George, Synucleins in synaptic plasticity and neurodegenerative disorders.	
		J. Neurosci. Res., 58: 120-129, 1999	
		Clarke, Developmental cell death: morphological diversity and multiple mechanisms.	
		Anat. Embryol. (Berl), 181: 195-213, 1990	
		Conway et al., Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.	
		Nat. Med., 11: 1318-1320, 1998	
↓		Fahn and Przedborski, Parkinsonism. In: Merritt's textbook of neurology, Ed 10 (Rowland LP, ed), pp 679-693. Philadelphia: Williams & Wilkins 2000	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
PK		Figueiredo-Pereira et al., A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces	
		accumulation of ubiquitin-protein conjugates in a neuronal cell.	
		J. Neurochem., 63: 1578-1581, 1994	
		Fon et al., Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action.	
		Neuron, 19: 1271-1283, 1997	
		Forno and Norville, Ultrastructure of Lewy bodies in the stellate ganglion.	
		Acta. Neuropathol. (Berl), 34: 183-197, 1976	
		Furlong et al., Alpha-synuclein over expression promotes aggregation of mutant huntingtin.	
		Biochem. J., 15: 577-581, 2000	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1832~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Ghee et al., Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex.	
		J. Neurochem., 75: 2221-2224, 2000	
		Goldstein and Greene, Activation of tyrosine hydroxylase by phosphorylation. In: Psychopharmacology: a third generation of progress	
		(Meltzer H, ed), pp 75-80. New York: Raven, 1987	
		Greene and Tischler, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.	
		Proc. Natl. Acad. Sci. USA 73: 2424-2428, 1976	
		Greene, et al., Culture and experimental use of the PC12 rat pheochromocytoma cell line. In: Culturing nerve cells (Banker G, Goslin K, eds), pp 161-189.	
		Cambridge, MA: MIT Press, 1998; Stefanis et al., 2001, supra).	
		Hornykiewicz, Dopamine (3-hydroxytyramine) and brain function.	
↓		Pharmacol. Rev., 18: 925-965, 1996	

Examiner Signature	/Daniel E. Kolker/	Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JK		Hsu et al., Alpha-Synuclein promotes mitochondrial deficit and oxidative stress.	
		Am. J. Pathol., 157: 401-410, 2000	
		Imai et al., An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin.	
		Cell, 105: 891-902, 2001	
		Kanda et al., Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.	
		Neuroscience, 97: 279-284, 2000	
		Kegel et al., Huntingtin expression stimulates endosomal-lysosomal activity, endosome tabulation, and autophagy.	
		J. Neurosci., 20: 7268-7278, 2000	
		Kitada et al., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.	
✓		Nature, 392: 605-608, 1998	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Leroy et al., The ubiquitin pathway in Parkinson's disease.	
		Nature, 395: 451-452, 1998	
		Masliah et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.	
		Science, 287: 1265-1269, 2000	
		Matsuoka et al., Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.	
		Neurobiol. Dis., 8: 535-539, 2001	
		Mayer et al., Ubiquitin, lysosomes, and neurodegenerative diseases.	
		Ann. NY Acad. Sci., 674: 149-160, 1992	
		McNaught and Jenner, Proteasomal function is impaired in substantia nigra in Parkinson's disease.	
		Neurosci. Lett., 297: 191-194, 2001	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		McNaught et al., Failure of the ubiquitin-proteasome system in Parkinson's disease.	
		Nat. Rev. Neurosci., 2: 589-594, 2001	
		Neystat, et al., Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease.	
		Mov. Disord., 14: 417-422, 1999	
		Ohsawa et al., An ultrastructural and immunohistochemical study of PC12 cells during apoptosis induced by serum deprivation with special reference	
		to autophagy and lysosomal cathepsins.	
		Arch. Histol. Cytol., 61: 395-403, 1998	
		Ohtani-Kaneko et al., Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of	
		multi-ubiquitin chains.	
		Neurochem. Res., 23: 1435-1443, 1998	

Examiner Signature		Date Considered	2/2/06.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JK		Ostrerova et al., Alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.	
		J. Neurosci., 19: 5782-5791, 1999	
		Ostrerova-Golts et al., The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.	
		J. Neurosci., 20: 6048-6054, 2000	
		Papadimitriou et al., Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology, 52: 651-654, 1999	
		Neurology, 52: 651-654, 1999	
		Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.	
		Science, 276: 2045-2047, 1997	
		Pothos et al., Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size.	
✓		J. Neurosci., 20: 7297-7306, 2000	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Rathke-Hartlieb et al., Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant-synuclein transgenic mice.	
		J. Neurochem., 77: 1181-1184, 2001	
		Rideout et al., Proteasomal inhibition leads to formation of ubiquitin / alpha-synuclein-immunoreactive inclusions in PC12 cells.	
		J. Neurochem., 78: 899-908, 2001	
		Rukenstein et al., Multiple agents rescue PC12 cells from serum-free cell death by translation- and transcription-independent mechanisms.	
		J. Neurosci., 11: 2552-2563, 1991	
		Saha et al., Induction of neuronal death by alpha-synuclein.	
		Eur. J. Neurosci., 12: 3073-3077, 2000	
		Seglen et al., Structural aspects of autophagy.	
✓		Adv. Exp. Med. Biol., 389: 103-111, 1996	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Shimura et al., Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for parkinson's disease.	
		Science, 293: 263-269, 2001	
		Shimura et al., Familial Parkinson disease gene product, parkin, is an ubiquitin-protein ligase.	
		Nat. Genet., 25: 302-305, 2000	
		Spillantini et al., Alpha-Synuclein in Lewy bodies.	
		Nature, 388: 839-840, 1997	
		Stefanis et al., Synuclein 1 is selectively upregulated in response to NGF treatment in PC12 cells.	
✓		J. Neurochem., 76: 1165-1176, 2001	

Examiner Signature	/David E. Kom/	Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Stefanis et al., Caspase-2 (Nedd2) processing and death of trophic factor-deprived PC12 cells and sympathetic neurons occur independently	
		of caspase-3 (CPP-32)-like activity.	
		J. Neurosci., 18: 9204-9215, 1998	
		Sulzer and Pothos, Presynaptic mechanisms that regulate quantal size.	
		Rev. Neurosci., 11: 159-212, 2000	
		Tabrizi et al., Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.	
		Hum. Mol. Genet., 9: 2683-2689, 2000	
		Tanaka et al., Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent	
		apoptosis.	
✓		Hum. Mol. Genet., 10: 919-926, 2001	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Tennyson et al., Structural abnormalities associated with congenital megacolon in transgenic mice that overexpress the Hoxa-4 gene.	
		Dev. Dyn., 98: 128-153, 1993	
		Tischler, et al., Morphological and cytochemical properties of a clonal line of rat adrenal pheochromocytoma cells which repond to nerve growth	
		factor.	
		Lab. Invest., 39(2): 77-89, 1978	
		Trojanowski et al., Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.	
		Cell Death Differ., 5: 832-837, 1998	
		Wojcik et al., Ubiquitin-mediated proteolysis centers in HeLa cells: indication from studies of an inhibitor of the chymotrypsin-like activity of	
		the proteasome.	
✓		Eur. J. Cell. Biol., 71: 311-318, 1996	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Xue et al., Autophagy is activated by apoptotic signaling in sympathetic neurons: an alternative mechanism of death execution.	
		Mol. Cell. Neurosci., 14: 180-198, 1999	
		Zhou et al., Over expression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-	
		derived cells.	
		Brain Res., 866: 33-43, 2000	
		Batistatou and Greene, Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor	
		deprivation: correlation with suppression of endonuclease activity.	
		J. Cell. Biol., 115: 461-471, 1991	
		Bennett et al., Degradation of alpha-synuclein by proteasome.	
✓		J. Biol. Chem., 274: 33855-33858, 1999	

Examiner Signature	/Jamie E. Kelly/	Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Drexler, Activation of the cell death program by inhibition of proteasome function.	
		Proc. Natl. Acad. Sci., USA, 94: 855-860, 1997	
		Giasson et al., Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro.	
		J. Biol. Chem., 274: 7619-7622, 1999	
		Greene, Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-	
		free medium.	
		J. Cell Biol., 78: 747-755, 1978	
		Imai et al., Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity.	
✓		J. Biol. Chem., 276: 35661-35664, 2000	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 16 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JK		Lopes et al., p53-dependent induction of apoptosis by proteasome inhibitors.	
		J. Biol.Chem., 272: 12893-12896, 1997	
		Mesner et al., Nerve growth factor withdrawal-induced cell death in neuronal PC12 cells resembles that in sympathetic neurons.	
		J. Cell. Biol., 119: 1669-1680, 1992	
		Obin et al., Neurite outgrowth in PC12 cells: distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis.	
		J. Biol. Chem., 274: 11789-11795, 1999	
		Spillantini et al., Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies.	
		Proc. Natl. Acad. Sci. USA, 95: 6469-6473, 1998	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 17 of 17

Complete if Known	
Application Number	10/737,262
Filing Date	12/15/03
First Named Inventor	Leonidas Stefanis
Art Unit	~~1632~~ 1649
Examiner Name	to be assigned
Attorney Docket Number	5199-26

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK		Stefanis et al., Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support.	
		J. Biol. Chem., 271: 30663-30671, 1996	
		Ueda, et al., Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's Disease.	
		Proc. Natl. Acad. Sci. USA, 90: 11282-11286, 1993	
		Zhang et al., parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein,	
		CDCrel-1.	
↓		Proc. Natl. Acad. Sci. USA, 97: 13354-13359, 2000	

Examiner Signature		Date Considered	2/2/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.